While all CLEAR phase 3 trials focused on lowering LDL-C as their primary endpoint, the CLEAR OUTCOME trial established cardiovascular benefit in terms of 4-component composite, “major adverse cardiovascular events” (MACE), and found it to be significantly reduced with bempedoic acid. It ...
Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases.doi:10.1097/crd.0000000000000218Nicole K ZagelbaumSrikanth YandrapalliChristopher NaborsWilliam H Frishman...
In this systematic review and meta-analysis, we searched Pubmed, Scopus and Cochrane library from inception to March 4, 2023. The search strategy for Pubmed is outlined in appendix and included terms as “bempedoic acid, LDL-C, hypercholesterolemia, cholesterol, lipoprotein, low-density lipoprotein...
Unfortunately, some of these strategies remain expensive, such as the use of proprotein convertase subtilisin/kexin type 9 inhibitors, thus new agents with more affordable cost/effectiveness ratio are welcome. Bempedoic acid is an interesting new opportunity to manage the complex scenario of ...
Role of Bempedoic Acid in Clinical Practice. Cardiovasc. Drugs Ther. 2021, 35, 853–864. [Google Scholar] [CrossRef] [PubMed] Jialal, I.; Ramakrishnan, N. Bempedoic acid: A novel oral LDL-cholesterol lowering agent. Int. J. Physiol. Pathophysiol. Pharmacol. 2022, 14, 84–89. [Google...